Luis E. Okamoto

Luis E. Okamoto

Auto-generated profile, based on publicly available information

Luis E. Okamoto

Vanderbilt Autonomic Dysfunction Center, Division of Clinical Pharmacology (L.E.O., A.D., C.A.S., A.G., B.K.B., S.Y.P., I.B.), Vanderbilt University Medical Center, Nashville, TN

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 February 2021 in Journal of Internal Medicine
Verified
Journal Article
Closed access
PDF file
KBKate M. Bourne
Kate M. Bourne
DCDerek S. Chew
Derek S. Chew
LSLauren E. Stiles
Lauren E. Stiles
BSBrett H. Shaw
Brett H. Shaw
CSCyndya A Shibao
Cyndya A Shibao
SRSatish R. Raj
Satish R. Raj

6 April 2021 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
LOLuis E. Okamoto
Luis E. Okamoto
JCJorge E. Celedonio
Jorge E. Celedonio
ESEmily C. Smith
Emily C. Smith
AGAlfredo Gamboa
Alfredo Gamboa
CSCyndya A Shibao
Cyndya A Shibao
IBItalo Biaggioni
Italo Biaggioni
Background: Supine hypertension affects a majority of patients with autonomic failure; it is associated with end‐organ damage and can worsen daytime orthostatic hypotension by inducing pressure diuresis and volume loss during the night. Because sympathetic activation prevents blood pressure (BP) from falling in healthy subjects exposed to heat, we hypothesized that passive heat had a BP‐lowering effect in patients with autonomic failure and could be used to treat their supine hypertension. Methods and Results: In Protocol 1 (n=22), the acute effects of local heat (40–42°C applied with a heating pad placed over the abdomen for 2 hours) versus sham control were assessed in a randomized crossover fashion. Heat acutely decreased systolic BP by −19±4 mm Hg (versus 3±4 with sham, P <0.001) owing to decreases in stroke volume (−18±5% versus −4±4%, P =0.013 ) and cardiac output (−15±5% versus −2±4%, P =0.013). In Protocol 2 (proof‐of‐concept overnight study; n=12), we compared the effects of local heat (38°C applied with a water‐perfused heating pad placed under the torso from 10 pm to 6 am ) versus placebo pill. Heat decreased nighttime systolic BP (maximal change −28±6 versus −2±6 mm Hg, P <0.001). BP returned to baseline by 8 am . The nocturnal systolic BP decrease correlated with a decrease in urinary volume ( r =0.57, P =0.072) and an improvement in the morning upright systolic BP ( r =−0.76, P =0.007). Conclusions: Local heat therapy effectively lowered overnight BP in patients with autonomic failure and supine hypertension and offers a novel approach to treat this condition. Future studies are needed to assess the long‐term safety and efficacy in improving nighttime fluid loss and daytime orthostatic hypotension. Registration: URL: https://www.clinicaltrials.gov ; Unique identifiers: NCT02417415 and NCT03042988.

2 March 2022 in Hypertension
Verified
Journal Article
Closed access
PDF file
NBNicholas C. Breier
Nicholas C. Breier
SPSachin Y. Paranjape
Sachin Y. Paranjape
SSShea Scudder
Shea Scudder
SMShahram E. Mehr
Shahram E. Mehr
ADAndre’ Diedrich
Andre’ Diedrich
CSCyndya A Shibao
Cyndya A Shibao
Background: Postural tachycardia syndrome (POTS) is characterized by excessive upright tachycardia and disabling presyncopal symptoms, which are exacerbated after consuming a high-carbohydrate meal; it is unknown, however, what is the precise underlying mechanism. We seek to investigate the effect of glucose intake on orthostatic hemodynamic changes and gastrointestinal hormone secretion in POTS. Methods: Prospective, case-control study, 12 women with POTS who reported a postprandial worsening of their POTS symptoms and 13 age-matched female controls received 75-g oral glucose and 20 mg/kg acetaminophen to assess nutrient absorption. Hemodynamic, gastrointestinal hormone and acetaminophen levels were measured for up to 120 minutes postingestion while supine and standing. Results: Patients with POTS had significant orthostatic tachycardia, 48.7±11.2 versus 23.3±8.1 bpm, P =0.012 and elevated upright norepinephrine levels, 835.2±368.4 versus 356.9±156.7 pg/mL, P =0.004. After oral glucose, upright heart rate significantly increased in POTS, 21.2±11.9% versus 6.0±19.9%, P =0.033 with a concomitant decline in upright stroke volume, −10.3±11.90% versus 3.3±13.7%, P =0.027; total peripheral resistance, blood pressure and cardiac output remained unaltered. Acetaminophen rate of appearance was similar between groups ( P =0.707), indicating comparable nutrient absorption rates. POTS had increased plasma levels of C-peptide ( P =0.001), GIP (glucose-dependent insulinotropic polypeptide; P =0.001), peptide YY ( P =0.016), and pancreatic polypeptide ( P =0.04) following glucose consumption, but only GIP had a time-dependent association with the worsening upright tachycardia and stroke volume fall. Conclusions: The glucose-induced worsening orthostatic tachycardia in POTS was associated with a decline in SV; these changes occurred while GIP, a splanchnic vasodilator, was maximally elevated.

1 March 2023 in Hypertension
Verified
Journal Article
Closed access
LOLuis E. Okamoto
Luis E. Okamoto
JCJorge E. Celedonio
Jorge E. Celedonio
ESEmily C. Smith
Emily C. Smith
SPSachin Y. Paranjape
Sachin Y. Paranjape
BBBonnie K. Black
Bonnie K. Black
IBItalo Biaggioni
Italo Biaggioni
Background: Supine hypertension affects most patients with orthostatic hypotension (OH) due to autonomic failure, but it is often untreated for fear of worsening OH. We hypothesized that increasing intrathoracic pressure with continuous positive airway pressure (CPAP) had a Valsalva-like blood-pressure-lowering effect that could be used to treat nocturnal supine hypertension in these patients, while reducing nocturnal pressure diuresis and improving daytime OH. Methods: In Protocol 1, we determined the acute hemodynamic effects of increasing levels of CPAP (0, 4, 8, 12, and 16 cm H 2 O, 3 minutes each) in 26 patients with autonomic failure and supine hypertension studied while awake and supine. In Protocol 2 (n=11), we compared the effects of overnight therapy with CPAP (8–12 cm H 2 O for 8 hours) versus placebo on nocturnal supine hypertension, nocturnal diuresis and daytime OH in a 2-night crossover study. Results: In Protocol 1, acute CPAP (4–16 cm H 2 O) decreased systolic blood pressure in a dose-dependent manner (maximal drop 22±4 mmHg with CPAP 16) due to reductions in stroke volume (−16+3%) and cardiac output (−14±3%). Systemic vascular resistance and heart rate remained unchanged. In Protocol 2, overnight CPAP lowered nighttime systolic blood pressure (maximal change −23±5 versus placebo −1±7 mmHg; P =0.023) and was associated with lower nighttime diuresis (609±84 versus placebo 1004±160 mL; P =0.004) and improved morning orthostatic tolerance (AUC upright SBP 642±121 versus placebo 410±109 mmHg*min; P =0.014). Conclusions: CPAP is a novel nonpharmacologic approach to treat the supine hypertension of autonomic failure while improving nocturia and daytime OH. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03312556.

25 January 2021 in Hypertension
Verified
Journal Article
Closed access
PDF file
ACAbby H. Chopoorian
Abby H. Chopoorian
AWAmr Wahba
Amr Wahba
JCJorge Celedonio
Jorge Celedonio
VNVictor Nwazue
Victor Nwazue
ESEmily C. Smith
Emily C. Smith
AGAlfredo Gamboa
Alfredo Gamboa
The purpose of this study is to evaluate endothelial function in postural tachycardia syndrome (PoTS), a poorly understood chronic condition characterized by a state of consistent orthostatic tachycardia (delta heart rate ≥30 beats per minute) upon standing without orthostatic hypotension. Nineteen patients with PoTS and 9 healthy controls were studied after 3 days of a fixed, caffeine-free, normal sodium (150 milliequivalents/day) diet. All participants underwent autonomic function testing, including sinus arrhythmia, valsalva maneuver, hyperventilation, cold pressor, handgrip, and a standing test with catecholamine measurements, followed by endothelial function testing. We analyzed 3 measures of endothelial function: percent brachial flow-mediated dilation, digital pulsatile arterial tonometry, and postischemic percent leg blood flow. Flow-mediated dilation was significantly lower in patients with PoTS (6.23±3.54% for PoTS) than in healthy controls (10.6±4.37% for controls versus, P =0.014). PoTS and controls had similar digital pulsatile arterial tonometry (1.93±0.40 arbitrary units for controls versus 2.13±0.63 arbitrary units for PoTS). PoTS had similar but suggestive percent leg blood flow to controls (313±158% for PoTS versus 468±236% for controls, P =0.098). Patients with PoTS have significantly reduced flow-mediated dilation compared with healthy controls, suggesting that PoTS is characterized by endothelial dysfunction in conduit arteries. Registration: URL: https://www.clinicaltrials.gov . Unique identifier: NCT01308099.

1 November 2024 in Hypertension
Verified
Journal Article
Closed access
LOL.E. Okamoto
L.E. Okamoto
VUV. Urechie
V. Urechie
SRS. Rigo
S. Rigo
JAJ.J. Abner
J.J. Abner
MGM. Giesecke
M. Giesecke
IBItalo Biaggioni
Italo Biaggioni
BACKGROUND: A subset of patients with postural tachycardia syndrome (POTS) are thought to have a primary hyperadrenergic cause. We assessed clinical biomarkers to identify those that would benefit from sympatholytic therapy. METHODS: We measured sympathetic function (supine muscle sympathetic nerve activity, upright plasma norepinephrine, and blood pressure responses to the Valsalva maneuver) in 28 patients with POTS (phenotyping cohort) to identify clinical biomarkers that are associated with responsiveness to the central sympatholytic guanfacine in a separate uncontrolled treatment cohort of 38 patients that had received guanfacine clinically for suspected hyperadrenergic POTS (HyperPOTS). RESULTS: In the phenotyping cohort, an increase in diastolic blood pressure (DBP) >17 mm Hg during late phase 2 of the Valsalva maneuver identified patients with the highest quartile of resting muscle sympathetic nerve activity (HyperPOTS) with 71% sensitivity and 85% specificity. In the treatment cohort, patients with HyperPOTS, identified by this clinical biomarker, more often reported clinical improvement (85% versus 44% in nonhyperadrenergic; P =0.016), had better orthostatic tolerance (∆Orthostatic Hypotension Daily Activities Scale: −1.9±0.9 versus 0.1±0.5; P =0.032), and reported less chronic fatigue (∆PROMIS Fatigue Short Form 7a: −12.9±2.7 versus −2.2±2.2; P =0.005) in response to guanfacine. CONCLUSIONS: These results are consistent with the concept that POTS is caused by a central sympathetic activation in a subset of patients, which can be identified clinically by an exaggerated DBP increase during phase 2 of the Valsalva maneuver and improved by central sympatholytic therapy. These results support further clinical trials to determine the safety and efficacy of guanfacine in patients with POTS enriched for the presence of this clinical biomarker.